A hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin.
Indicated for adult patients with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.
Not useful as monotherpay for treatment of Hepatitis C
The most common side effects of VICTRELIS in combination with peginterferon alfa and ribavirin include tiredness, nausea, headache and a change in taste.
Dose: 800 mg administered orally three times daily.
Use with protease inhibitors used in HIV/AIDS can reduce the effects of thes medications, by reducing levels of these drugs and may increase viral loads.
May have harmful interactions with calcium channel blockers and alpha-1-adrenergic receptor antagonists.